Hims & Hers Health (NYSE:HIMS) Faces Class Action After Partnership Termination With Novo Nordisk

Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company's share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a remarkable quarterly earnings report with substantial sales and net income growth, these...